Mode
Text Size
Log in / Sign up
N/A N=239 Randomized Treatment

Clinical Trial Comparing Decompression With and Without Coflex™ Interlaminar Technology Treating Lumbar Spinal Stenosis

Spinal Stenosis

Enrolled (actual)
239
Serious AEs
77.4%
Results posted
Jun 2020
Primary outcome: Primary: Change in ODI From Baseline to 24 Months — -19.0; -22.5 percentage points

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Implantation of coflex™ after surgical decompression (Device); Surgical decompression (Procedure)
Age
Adult, Older Adult · 40+ yrs
Sex
All
Sponsor
Paradigm Spine
Primary completion
Aug 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in ODI From Baseline to 24 Months
-19.0; -22.5
SECONDARY
Number of Participants With Significant Migration or Expulsion of the Implant
2
SECONDARY
Change in Visual Analog Scale (VAS) Back Pain From Baseline to 24 Months
-23.5; -23.1
SECONDARY
Change in Visual Analog Scale (VAS) Leg Pain From Baseline to 24 Months
-24.3; -20.6
SECONDARY
Neurological Status - Mean Change in Sensory Deficit From Baseline to 24 Months
0.03; 0.04
SECONDARY
Assessment of Time to Symptoms Utilizing Walking Distance Test
6.01; 4.36
SECONDARY
Number of Participants With Adverse Events - Operative Site
45; 54
SECONDARY
The Percentage of Patients With Survival Probability as Assessed by Evaluating Treatment Failure in Both Groups..
0.79; 0.76
SECONDARY
Change of Symptoms- Zurich Claudication Questionnaire (ZCQ) After 24 Months Compared to Baseline.
-15.0; -15.10
SECONDARY
Change in Functionality- Zurich Claudication Questionnaire (ZCQ) From Baseline to 24 Months
-3.98; -3.52
SECONDARY
Neurological Status - Mean Change in Muscle Strength From Baseline to 24 Months
0.002; -0.030
SECONDARY
Assessment of Neurological Status Using the Laségue Test or Straight Leg Raise Test- Change From Baseline to 24 Months
10.8; 9.6
SECONDARY
Number of Participants Receiving Epidural Injections
0; 2
SECONDARY
Neurological Status- Mean Change in Trendelenburg Sign Test From Baseline to 24 Months.
-0.08; -0.05
SECONDARY
Neurological Status- Mean Change in Ilio Sacral Joint Affection Test From Baseline to 24 Months.
-0.10; -0.07

Summary

A 2 year comparative evaluation of clinical outcome in the treatment of degenerative spinal stenosis with concomitant low back pain by decompression with and without additional stabilization using the coflex® Interlaminar Technology

Eligibility Criteria

Inclusion Criteria

  • Radiographic confirmation of clinical symptoms of at least moderate degenerative spinal stenosis, with constriction of the central spinal canal of one or two adjacent segments in the region L3 to L5 with the need for decompression.

If necessary additional decompression in the adjacent segment(s) may be performed avoiding any instability in the affected segment.

In addition the following may exist (but is not obligatory):

  • hypertrophy of the facet joints and subarticular recessus stenosis in the relevant segment or
  • stenosis of the foramen in the relevant segment
  • and/or stable retrolisthesis up to grade I verified by flexion-/extension X-ray films.
  • Radiographic confirmation of no translatory instability in the main segment as well as in adjacent segments (dynamic translatory instability ≤ 3 mm).
  • VAS back pain score of at least 50 mm on a 100 mm scale (for acute back pain or a period of at least 3 month of back pain before the onset of leg pain).
  • Minimum of 3 months conservative therapy without improvement of symptoms.
  • Age >40 years.
  • Oswestry Low Back Pain Disability Questionnaire score of at least 18/45 (40%) for German sites or 20/50 (40%) for the US sites (The question about sexual life will be excluded).
  • Suitability of the patient for a posterior surgery procedure.
  • Mental and physical ability of patient to follow the protocol according to compliance to time schedule, treatment plan, fill in of CRF pages and further study procedures.
  • Personally signed informed consent form before the start of any study related procedures.

Exclusion Criteria

Any of the following will exclude a subject from the study:

  • Preceding fusion or decompression surgery of the lumbar spine or preceding nucleotomy of the segments of concern (also if nucleotomy becomes necessary during surgery).
  • Radiographically confirmed damage of the vertebral body in the segment of concern in the lumbar spine (e.g. osteoporotic compression fracture or because of tumors)
  • Isthmic and degenerative spondylolisthesis (anterolisthesis; retrolisthesis > grade I) or spondylolysis (Pars fracture).
  • Degenerative lumbar scoliosis (> 25°).
  • Adipositas (obesity). Defined as a body mass index >40.
  • Pregnancy, or wish to get pregnant during the course of the study.
  • Known allergy for titanium and titanium alloys.
  • Fluoride infections - both systemic and local.
  • History of severe peripheral neuropathy.
  • Significant peripheral vascular disease (claudication intermittens ≥ stage 2b).
  • M. Paget or osteomalacia or other metabolic bone disorders.
  • Cauda equina syndrome.
  • Communicating diseases, including HIV, active hepatitis
  • Patients who are lawfully kept in an institution.
  • Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this clinical trial or will not comply with requirements of the study.
  • Subjects who participated in a clinical observation or therapy with X-ray during the last 10 years.
  • Subjects who participate(d) in another clinical trial (within the last 4 weeks) that might influence the safety and effectiveness assessment of this trial.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01316211). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search